Successful treatment of pyrotinib for bone marrow metastasis induced pancytopenia in a patient with non‐small‐cell lung cancer and ERBB2 mutation

ERBB2 mutations are found in about 2% of patients with non‐small cell lung cancer (NSCLC). A recent study reported that pyrotinib (an irreversible pan ErbB inhibitor) had superior antitumor effect compared to other tyrosine kinase inhibitor therapies in patients with ERBB2 mutations. Bone marrow met...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Yanyan, Ni, Jun, Chang, Xiaoyan, Zhang, Xiaotong, Zhang, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2020
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7327666/
https://www.ncbi.nlm.nih.gov/pubmed/32458584
http://dx.doi.org/10.1111/1759-7714.13480

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7327666/
https://www.ncbi.nlm.nih.gov/pubmed/32458584
http://dx.doi.org/10.1111/1759-7714.13480

Ejemplares similares